ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is a Healthcare company (Biotechnology) with a market capitalization of $829M. The Maz Rating grades it against the other companies in its sector.
ORIC Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.00, ORIC Pharmaceuticals, Inc. trades at 2.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -41.0%, return on invested capital of -49.5% and a free cash flow yield of -15.5%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 11.09. Over the past 52 weeks the share price ranged from $7.23 to $14.68, with a beta of 0.98.
ORIC Pharmaceuticals, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 12 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, ORIC Pharmaceuticals, Inc. (ORIC) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.26% / 30% · (Cash+Inv) / Mkt Cap (36m) 26.9% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.26% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 20.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.26% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 20.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.62% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 67.4% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.91% / 33.33% · (Cash+ST Inv) / Total Assets 71.2% / 33.33% · (Cash+Recv) / Total Assets 71.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, ORIC Pharmaceuticals, Inc. (ORIC) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. ORIC Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
ORIC Pharmaceuticals, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.